LTFS
JNCE

Ladenburg Thalmann Financial Services’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Hold
200
– – ﹤0.01% 5127
2019
Q3 		$1K Hold
200
– – ﹤0.01% 5194
2019
Q2 		$1K Hold
200
– – ﹤0.01% 5193
2019
Q1 		$1K Hold
200
– – ﹤0.01% 5149
2018
Q4 		$1K Hold
200
– – ﹤0.01% 5125
2018
Q3 		$1K Buy
+200
New +$1.49K ﹤0.01% 5070

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ladenburg Thalmann Financial Services's JNCE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q4 2019 at 200 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5127.

Ladenburg Thalmann Financial Services first reported a position in JNCE in Q3 2018 and has held it in 6 quarters since. 100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 200 shares of Jounce Therapeutics, Inc. Common Stock worth $2K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q4 2019.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5127 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 6 quarters since.
  • 100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.